Мы используем Cookies Этот веб-сайт использует cookie-файлы, чтобы предлагать вам наиболее актуальную информацию. Просматривая этот веб-сайт, Вы принимаете cookie-файлы.
Methods: Electronic databases were searched using terms related to frontotemporallobardegeneration and movement disorders.
2
Mutations in the gene encoding PGRN give rise to shortage of PGRN and cause familial frontotemporallobardegeneration.
3
Summary: This represents the first systematic review and meta-analysis of the occurrence of movement disorder phenomenology in genetic frontotemporallobardegeneration.
4
These findings further highlight that plasma PGRN levels may not accurately predict clinical features or response to future frontotemporallobardegeneration therapies.
5
Mutations in various RBPs cause several diseases of the central nervous system, including frontotemporallobardegeneration, amyotrophic lateral sclerosis and fragile X syndrome.
Использование термина ftld на английском
1
Objective: To compare demographic characteristics of patients in the 3 FTLD subgroups.
2
Results: The frontotemporal dementia subgroup represented approximately half of all FTLD diagnoses.
3
The publication of consensus criteria for FTLD, however, prompted systematic studies.
4
FTLD is a more common form of dementia than previously recognized.
5
Recent findings have shown that this domain is hypomethylated in patients with FTLD-FUS.
6
In most ALS and FTLD cases, the predominant pathological species are RNA-binding proteins.
7
Extrapyramidal motor symptoms were more likely to be present in FTLD.
8
However, no increases were observed in any of the five factor scores in FTLD.
9
Autopsy in three family members showed a consistent and unique subtype of FTLD-TDP pathology.
10
Hence, ALS and FTLD converge in pathogenic pathways disrupting the regulation of RNA processing.
11
The sex and age-at-onset differences suggest that there may be biological differences among FTLD subgroups.
12
There was no significant FTLD or motor neuron disease.
13
This suggests additional variants and genes that remain to be identified as risk factors for FTLD.
14
These findings highlight this process as a novel and promising therapeutic target for ALS and FTLD.
15
Moreover, 19 proteins were selectively decreased in FTLD-U.
16
The present review aims to underscore the necessity of further elucidation of PGRN biology in FTLD-related neurodegeneration.